NEW YORK (GenomeWeb) – Agilent Technologies' Dako business said today that it will develop a companion diagnostic test for a cancer drug being developed by Merck.

The test will be for the analysis of the potential tumor biomarker PD-L1 as an aid in treating cancer patients with Merck's investigational anti-PD-1 antibody. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.